Compugen Ltd. (NASDAQ:
CGEN) today announced that certain aspects of its predictive
approach to therapeutics discovery as applied to novel immune
checkpoints will be presented in poster sessions at three leading
scientific conferences this month and next. The presentations also
include experimental results from some of the immune checkpoint based
product candidate programs addressing cancer immunotherapy and
autoimmune diseases now being pursued by the Company:
-
At the Cancer Research Institute’s 22nd
Annual International Cancer Immunotherapy Symposium, being held on
October 6-8, 2014 in New York City, Ilan Vaknin, PhD, Senior
Scientist, Immunology Research and Discovery at Compugen, will present
the predictive discovery of novel immune checkpoint targets for cancer
immunotherapy. Certain validation data relating to CGEN-15049 and
CGEN-15052, two of the eleven novel B7/CD28-like immune checkpoint
candidates discovered by Compugen, will be included in the poster
presentation.
-
At the Society
for Immunotherapy of Cancer Annual Meeting, to be held November
6-9, 2014, in National Harbor, MD, Galit Rotman, PhD, Chief Scientist,
Therapeutics at Compugen, will also present the predictive discovery
of novel immune checkpoint targets for cancer immunotherapy. Dr.
Rotman’s presentation will include certain validation data relating to
selected B7/CD28-like immune checkpoint candidates discovered by the
Company.
-
At the American
College of Rheumatology Annual Meeting 2014, to be held on
November 14-19, 2014, in Boston, Iris Hecht, PhD, Principal Scientist
at Compugen, will present results for CGEN-15001 for the potential
treatment of autoimmune diseases such as rheumatoid arthritis,
multiple sclerosis and type 1 diabetes. CGEN-15001 is a novel Fc
fusion protein drug candidate based on one of the eleven
Compugen-discovered B7/CD28-like immune checkpoint candidates.
About Compugen
Compugen is a leading drug discovery company focused on therapeutic
proteins and monoclonal antibodies to address important unmet needs in
the fields of immunology and oncology. The Company utilizes a broad and
continuously growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in
silico (by computer) prediction and selection of product candidates,
which are then advanced in its Pipeline Program. The Company's business
model includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. Compugen’s
wholly-owned U.S. subsidiary located in South San Francisco is
developing monoclonal antibody therapeutic candidates against its novel
drug targets. For additional information, please visit Compugen's
corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of terminology
such as “will,” “may,” “expects,” “anticipates,” “believes,” and
“intends,” and describe opinions about future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these and other factors are
discussed in the "Risk Factors" section of Compugen’s most recent Annual
Report on Form 20-F as filed with the Securities and Exchange Commission
as well as other documents that may be subsequently filed by Compugen
from time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen’s views only
as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements unless
required by law.
Copyright Business Wire 2014